Fusion proteins containing a BDNF and an anti-human transferrin receptor antibody

Patent metadata

Field	Value
Publication number	US-11130815-B2
Application number	US-201615739199-A
Country	US
Kind code	B2
Filing date	Jun 24, 2016
Priority date	Jun 24, 2015
Publication date	Sep 28, 2021
Grant date	Sep 28, 2021

Abstract

Disclosed is a fusion protein containing a brain-derived neurotrophic factor (BDNF). The fusion protein is a fusion protein of BDNF and a specific range of human anti-transferrin receptor antibody, which makes BDNF administered into the blood able to pass through the blood-brain barrier.

First claim

The invention claimed is:

1. A fusion protein of brain-derived neurotrophic factor (BDNF) and an anti-human transferrin receptor (anti-hTfR) antibody, wherein the fusion protein comprises a BDNF linked to an anti-hTfR antibody or antigen-binding fragment thereof; wherein the anti-hTfR antibody or antigen-binding fragment thereof comprises a light chain (LC) having a light chain variable region (LCVR) comprising three complementarity-determining regions (LCDR1-3) and a heavy chain (HC) having a heavy chain variable region (HCVR) comprising three complementarity-determining regions (HCDR1-3), wherein the LCDR1 comprises the amino acid sequence of SEQ ID NO:16, the LCDR2 comprises the amino acid sequence of SEQ ID NO:18, the LCDR3 comprises the amino acid sequence of SEQ ID NO:20, the HCDR1 comprises the amino acid sequence of SEQ ID NO:88, the HCDR2 comprises the amino acid sequence of SEQ ID NO:90, and the HCDR3 comprises the amino acid sequence of SEQ ID NO:92, and wherein the BDNF is linked directly or via a linker to the HC of the anti-hTfR antibody or antigen-binding fragment thereof and the C-terminus of the BDNF is linked to the N-terminus of the HC.

2. The fusion protein according to claim 1 , wherein the LCVR comprises the amino acid sequence of SEQ ID NO:191, and the HCVR comprises the amino acid sequence of SEQ ID NO:205.

3. The fusion protein according to claim 1 , wherein the LCVR comprises the amino acid sequence having at least 95% sequence identity to SEQ ID NO:191 and having the LCDR1-3 of SEQ ID NOs:16, 18 and 20 respectively, and the HCVR comprises the amino acid sequence having at least 95% sequence identity to SEQ ID NO:205 and having the HCDR1-3 of SEQ ID NOs: 88, 90 and 92 respectively.

4. The fusion protein according to claim 3 , wherein the LCVR comprises the amino acid sequence having at least 98% sequence identity to SEQ ID NO:191 and having the LCDR1-3 of SEQ ID NOs:16, 18 and 20 respectively, and the HCVR comprises the amino acid sequence having at least 98% sequence identity to SEQ ID NO:205 and having the HCDR1-3 of SEQ ID NOs: 88, 90 and 92 respectively.

5. The fusion protein according to claim 1 , wherein the LCVR comprises the amino acid sequence of SEQ ID NO:191 with a substitution, deletion or addition of 1 to 3 amino acids and has the LCDR1-3 of SEQ ID NOs:16, 18 and 20 respectively, or wherein the HCVR comprises the amino acid sequence of SEQ ID NO:205 with a substitution, deletion or addition of 1 to 3 amino acids and has the HCDR1-3 of SEQ ID NOs: 88, 90 and 92 respectively.

6. The fusion protein according to claim 1 , wherein the antigen-binding fragment is a Fab, F(ab′) 2 , or F(ab′) of the anti-hTfR antibody and the BDNF is human BDNF; wherein the human BDNF is linked, directly or via a linker, to the heavy chain of the Fab, F(ab′) 2 , or F(ab′).

7. The fusion protein according to claim 6 , wherein the light chain of the antigen-binding fragment consists of the amino acid sequence of SEQ ID NO:196, and the heavy chain of the antigen-binding fragment consists of the amino acid sequence of SEQ ID NO:261.

8. The fusion protein according to claim 6 , wherein the light chain consists of the amino acid sequence of SEQ ID NO:196, and the BDNF linked to the heavy chain of the antigen-binding fragment consists of the amino acid sequence of SEQ ID NO:263.

9. The fusion protein according to claim 6 , wherein the light chain consists of the amino acid sequence of SEQ ID NO:196, and the BDNF linked to the heavy chain of the antigen-binding fragment consists of the amino acid sequence of SEQ ID NO:264.

10. The fusion protein according to claim 1 , wherein the linker is a peptide consisting of 1 to 50 amino acid residues.

11. The fusion protein according to claim 1 , wherein the linker is a peptide comprising the amino acid sequence selected from the group consisting of the amino acid sequence (Gly-Ser), the amino acid sequence (Gly-Gly-Ser), SEQ ID NO:3, SEQ ID NO:4, and SEQ ID NO:5.

12. The fusion protein according to claim 1 , wherein the BDNF is human BDNF.

13. The fusion protein according to claim 12 , wherein the human BDNF comprises the amino acid sequence having an identity not lower than 97% to the amino acid sequence set forth as SEQ ID NO:247, or
the human BDNF comprises the amino acid sequence having an identity not lower than 97% to the amino acid sequence set forth as SEQ ID NO:256.

14. The fusion protein according to claim 1 , having an affinity to both the extracellular region of human transferrin receptor and the extracellular region of monkey transferrin receptor.

15. The fusion protein according to claim 14 , wherein the dissociation constant of the anti-transferrin receptor antibody with the extracellular region of human transferrin receptor is not greater than 1×10 −8 M, and the dissociation constant of the anti-transferrin receptor antibody with the extracellular region of monkey transferrin receptor is not greater than 5×10 −8 M.

16. A fusion protein of brain-derived neurotrophic factor (BDNF) and an anti-human transferrin receptor (anti-hTfR) antibody, wherein the fusion protein comprises a BDNF linked to an anti-hTfR scFv antibody, wherein the anti-hTfR scFv antibody comprises a light chain variable region (LCVR) comprising three complementarity-determining regions (LCDR1-3) and a heavy chain variable region (HCVR) comprising three complementarity-determining regions (HCDR1-3), wherein the LCDR1 comprises the amino acid sequence of SEQ ID NO:16, the LCDR2 comprises the amino acid sequence of SEQ ID NO:18, the LCDR3 comprises the amino acid sequence of SEQ ID NO:20, the HCDR1 comprises the amino acid sequence of SEQ ID NO:88, the HCDR2 comprises the amino acid sequence of SEQ ID NO:90, and the HCDR3 comprises the amino acid sequence of SEQ ID NO:92, wherein the BDNF is human BDNF, and wherein the C-terminus of the BDNF is linked to the N-terminus of the HCVR via a first linker and the C-terminus of the HCVR is linked to the N-terminus of the LCVR via a second linker.

17. The fusion protein according to claim 16 , wherein the HCVR comprises the amino acid sequence of SEQ ID NO:205.

18. The fusion protein according to claim 16 , wherein the linker consists of 2 to 50 amino acid residues.

19. The fusion protein according to claim 18 , wherein the linker comprises the amino acid sequence selected from the group consisting of the amino acid sequence (Gly-Ser), the amino acid sequence (Gly-Gly-Ser), the amino acid sequence (Gly-Gly-Gly), SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and the amino acid sequence consisting of 2 to 10 thereof that are consecutively linked.

20. The fusion protein according to claim 16 , wherein the anti-hTfR scFv antibody consists of the amino acid sequence of SEQ ID NO:257.

21. The fusion protein according to claim 20 , wherein the anti-hTfR scFv antibody consists of the amino acid sequence of SEQ ID NO:257, the human BDNF is human pro-BDNF, and the fusion protein comprises the amino acid sequence of SEQ ID NO:259.

22. The fusion protein according to claim 20 , wherein the anti-hTfR scFv antibody consists of the amino acid sequence of SEQ ID NO:257, and the fusion protein comprises the amino acid sequence of SEQ ID NO:260.

Assignees

• Japan Chem Res

Inventors

• Sonoda Hiroyuki
• Takahashi Kenichi

Classifications

• A61K47/6849

  the antibody targeting a receptor, a cell surface antigen or a cell surface determinant · CPC title

• C07K16/28 Primary

  against receptors, cell surface antigens or cell surface determinants · CPC title

• C12N15/09

  Recombinant DNA-technology · CPC title

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• A61K39/395

  Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum · CPC title